X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs AJANTA PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA AJANTA PHARMA ELDER PHARMA/
AJANTA PHARMA
 
P/E (TTM) x -0.2 21.6 - View Chart
P/BV x 0.1 5.1 2.0% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ELDER PHARMA   AJANTA PHARMA
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
AJANTA PHARMA
Mar-18
ELDER PHARMA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs3801,818 20.9%   
Low Rs1881,106 17.0%   
Sales per share (Unadj.) Rs491.2239.5 205.1%  
Earnings per share (Unadj.) Rs-3.252.8 -6.0%  
Cash flow per share (Unadj.) Rs14.459.5 24.2%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs376.5230.0 163.7%  
Shares outstanding (eoy) m20.5488.77 23.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.66.1 9.5%   
Avg P/E ratio x-89.327.7 -322.3%  
P/CF ratio (eoy) x19.724.6 80.2%  
Price / Book Value ratio x0.86.4 11.9%  
Dividend payout %00-   
Avg Mkt Cap Rs m5,833129,782 4.5%   
No. of employees `000NA6.8 0.0%   
Total wages/salary Rs m2,1793,765 57.9%   
Avg. sales/employee Rs ThNM3,128.4-  
Avg. wages/employee Rs ThNM554.0-  
Avg. net profit/employee Rs ThNM689.7-  
INCOME DATA
Net Sales Rs m10,08921,258 47.5%  
Other income Rs m257242 106.2%   
Total revenues Rs m10,34621,499 48.1%   
Gross profit Rs m-7926,584 -12.0%  
Depreciation Rs m361596 60.6%   
Interest Rs m2,7564 67,226.8%   
Profit before tax Rs m-3,6536,226 -58.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m1251,539 8.1%   
Profit after tax Rs m-654,686 -1.4%  
Gross profit margin %-7.831.0 -25.3%  
Effective tax rate %-3.424.7 -13.9%   
Net profit margin %-0.622.0 -2.9%  
BALANCE SHEET DATA
Current assets Rs m9,24012,236 75.5%   
Current liabilities Rs m9,9983,461 288.9%   
Net working cap to sales %-7.541.3 -18.2%  
Current ratio x0.93.5 26.1%  
Inventory Days Days4660 76.9%  
Debtors Days Days6084 70.9%  
Net fixed assets Rs m10,12411,140 90.9%   
Share capital Rs m206177 116.3%   
"Free" reserves Rs m5,58220,237 27.6%   
Net worth Rs m7,73420,414 37.9%   
Long term debt Rs m4,88910 48,405.9%   
Total assets Rs m22,88224,486 93.4%  
Interest coverage x-0.31,519.4 -0.0%   
Debt to equity ratio x0.60 127,774.5%  
Sales to assets ratio x0.40.9 50.8%   
Return on assets %11.819.2 61.4%  
Return on equity %-0.823.0 -3.7%  
Return on capital %22.330.5 73.1%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m30711,667 2.6%   
Fx outflow Rs m1251,616 7.8%   
Net fx Rs m18110,052 1.8%   
CASH FLOW
From Operations Rs m11,7542,854 411.8%  
From Investments Rs m-561-2,604 21.5%  
From Financial Activity Rs m-6,762-2 338,090.0%  
Net Cashflow Rs m4,432248 1,786.3%  

Share Holding

Indian Promoters % 39.6 73.8 53.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 1.6 483.9%  
FIIs % 16.8 7.6 221.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 17.0 212.4%  
Shareholders   16,479 20,968 78.6%  
Pledged promoter(s) holding % 77.6 4.4 1,766.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  GLENMARK PHARMA  GSK PHARMA  PANACEA BIOTECH  

Compare ELDER PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 11.6% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 11.6% YoY). Sales on the other hand came in at Rs 5 bn (up 8.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 17.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, AJANTA PHARMA has posted a net profit of Rs 945 m (down 17.1% YoY). Sales on the other hand came in at Rs 5 bn (up 11.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 8-QTR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS